Combining cytokine-induced killer cells with vaccination in cancer immunotherapy: More than one plus one?

被引：96

作者：

Thanendrarajan, Sharmilan ^{[1
]}

Nowak, Michael ^{[1
]}

Abken, Hinrich ^{[2
,3
]}

Schmidt-Wolf, Ingo G. H. ^{[1
]}

机构：

[1] Univ Bonn, Med Klin & Poliklin 3, CIO, D-53105 Bonn, Germany

[2] Univ Cologne, Innere Med Klin 1, CIO, Cologne, Germany

[3] Univ Cologne, Ctr Mol Med Cologne, CIO, Cologne, Germany

来源：

LEUKEMIA RESEARCH | 2011年 / 35卷 / 09期

关键词：

Immunotherapy; CIK cells; Dendritic cells; Vaccination; Clinical trials; Cancer; DENDRITIC CELLS; ANTITUMOR-ACTIVITY; CIK CELLS; PHASE-I; EFFECTOR-CELLS; T-CELLS; THERAPY; XENOGRAFT; TRANSPLANTATION; CHEMOTHERAPY;

D O I：

10.1016/j.leukres.2011.05.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

The immune system can be harnessed to fight cancer by active (stimulating the patient's intrinsic immune response to cancer) and by passive (transfer of active humoral or cellular immunity) immunotherapy. While for each strategy proof-of-principle was provided, clinical benefit was limited likely due to malfunction of lymphocytes. Increasing knowledge of both the mechanism of vaccination through dendritic cells (DCs) and the potency of a subset of natural killer T lymphocytes termed cytokine-induced killer (CIK) cells led to new strategies through combining adoptive and passive immunotherapy. This review summarizes most recent clinical trials indicating that CIK cells can substantially enhance the effect of tumor vaccines and discusses the potential therapeutic benefit in the long-term control of tumor progression. (C) 2011 Elsevier Ltd. All rights reserved.

引用

页码：1136 / 1142

页数：7

共 54 条

[1]

CD8+ T cell efficacy in vaccination and disease [J].

Appay, Victor ;

Douek, Daniel C. ;

Price, David A. .

NATURE MEDICINE, 2008, 14 (06) :623-628

[2]

Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: A preclinical study [J].

Chan, JK ;

Hamilton, CA ;

Cheung, MK ;

Karimi, M ;

Baker, J ;

Gall, JM ;

Schulz, S ;

Thorne, SH ;

Teng, NN ;

Contag, CH ;

Lum, LG ;

Negrin, RS .

CLINICAL CANCER RESEARCH, 2006, 12 (06) :1859-1867

[3]

Chang Xiao-Hong, 2008, Ai Zheng, V27, P1244

[4]

Chen Fu-xing, 2002, Ai Zheng, V21, P797

[5]

A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma [J].

Dong, Hui ;

Li, Qiang ;

Wang, Jian ;

Zhang, Ti ;

Kong, Da-Lu .

DIGESTIVE AND LIVER DISEASE, 2009, 41 (01) :36-41

[6]

Anti-tumoral capabilities of effector cells after IFN-α or CpG-motif treatment of cocultured dendritic cells [J].

Erhardt, Michael ;

Schmidt-Wolf, Ingo G. H. ;

Sievers, Elisabeth ;

Frank, Susanne ;

Strehl, John ;

von Lilienfeld-Toal, Marie ;

Gorschlueter, Marcus .

ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, 2006, 54 (06) :403-409

[7]

Ge Wei, 2004, Zhonghua Xue Ye Xue Za Zhi, V25, P277

[8]

Patient-derived dendritic cells transduced with an α-fetoprotein-encoding adenovirus and co-cultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against hepatocellular carcinoma cells [J].

González-Carmona, MA ;

Märten, A ;

Hoffmann, P ;

Schneider, C ;

Sievers, E ;

Schmidt-Wolf, IGH ;

Sauerbruch, T ;

Caselmann, WH .

LIVER INTERNATIONAL, 2006, 26 (03) :369-379

[9]

Gutgemann Stefan, 2007, Ger Med Sci, V5, pDoc07

[10]

Hontscha C, 2010, J CANC RES CLIN 0421, DOI [10.1007/s00432.010.0887.7, DOI 10.1007/S00432.010.0887.7]

← 1 2 3 4 5 6 →